Tag - AQST

Developments

USPTO grants Aquestive two patents for Anaphylm

Aquestive Therapeutics (NASDAQ: AQST) has announced that the USPTO has issued two additional patents extending protection into 2037 for Anaphylm, a novel epinephrine prodrug sublingual film. According to Aquestive, if...

October 8, 2025

Developments

IntelGenx, Aquestive in pact with men’s health company for Tadalafil oral films in U.S.

IntelGenx (TSXV:IGX; OTCQB:IGXT) and Aquestive Therapeutics (NASDAQ:AQST), its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction (ED) and benign prostatic...

September 30, 2021

Developments

IntelGenx and Aquestive Therapeutics in global collaboration for Tadalafil

IntelGenx (TSXV:IGX; OTCQX:IGXT) entered into a definitive worldwide agreement with Aquestive Therapeutics (NASDAQ:AQST), a specialty pharmaceutical company, for the co-development and commercialization of Tadalafil...

May 8, 2019

Tag - AQST

USPTO grants Aquestive two patents for Anaphylm

IntelGenx, Aquestive in pact with men’s health company for Tadalafil oral films in U.S.

IntelGenx and Aquestive Therapeutics in global collaboration for Tadalafil

Subscribe